Tiziana Life Sciences – Positive Data from Clinical Study of Nasal Administration with Foralumab February 2, 2021 – Posted in: Tiziana Life Sciences (TILS)

2nd February, 2021 THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil ·      Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting COVID-19, this therapeutic approach might also be useful for newly identified Covid-19 variants in UK, South Africa and Brazil.  ·      Foralumab is also the first monoclonal…